AVIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atea Pharmaceuticals Inc (AVIR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks positive catalysts, has weak technical indicators, and shows no significant trading sentiment or institutional interest. While there is an analyst price target increase, the company's financial performance and lack of growth trends do not support a compelling investment case currently.
The stock's MACD is negatively expanding (-0.0531), RSI is neutral at 36.7, and moving averages are converging, indicating no clear upward momentum. The stock is trading near its support level (S1: 5.478), but the overall trend is weak.
Evercore ISI raised the price target to $10 from $6 and maintained an Outperform rating.
No recent news, no significant hedge fund or insider trading activity, and no recent Congress trading data. The stock shows a 50% chance of declining in the short term (-2.78% in the next week).
In 2025/Q4, revenue remained at $0 with no YoY growth. Net income improved YoY by 33.76% but remains negative at -$44.87M. EPS improved by 42.50% to -0.57, but the company is still unprofitable.
Evercore ISI raised the price target to $10 from $6 and maintained an Outperform rating, indicating some optimism from analysts.
